Modified Cpf1 Guide RNA CRISPR Gene Editing Patent

The USPTO issued Patent US12606823B2 granting intellectual property protection for modified Cpf1 guide RNA CRISPR gene editing technology. The patent covers a nucleic acid comprising a Cpf1 crRNA with a 5′ processing sequence and extension sequence, compositions containing the nucleic acid with carriers, and methods for genetically modifying eukaryotic target cells.

For biotechnology and pharmaceutical manufacturers working with CRISPR gene editing technologies, this patent establishes intellectual property rights that may affect freedom-to-operate considerations for Cpf1-based gene editing applications. Parties developing or commercializing Cpf1 crRNA technologies should evaluate potential licensing requirements or design-around strategies.